Quantification of buparlisib in human liver microsomes employing an ultra-fast, sensitive UPLC-MS/MS method: in vitro and in silico metabolic stability evaluation.

Buparlisib (BLB) is an oral pan-phosphoinositide 3 kinase (PI3K) inhibitor that selectively targets all class I PI3K isoforms. No prior UPLC-MS/MS method with combined in silico metabolism analysis and green metrics for BLB has been reported, so this…

Preview only. Read the full abstract at the source